Orexin Receptors

Orexin receptor antagonists block orexin receptors 1 and 2 (OX1, OX2), which respond to orexin neuropeptides. Orexin A and orexin B were described in 1998 as hypothalamic peptides that act on these two G protein-coupled receptors. In 1999 a mutation in the orexin receptor 2 gene was found to cause canine narcolepsy. Mice lacking orexin showed a narcolepsy-like phenotype in the same year, linking the system to sleep and wakefulness. OX1 is also studied in reward, addiction and stress, and OX2 mainly in arousal. SB 334867, SB-408124 and GSK1059865 are OX1-selective antagonists, and MK-3697 targets OX2. Almorexant, TCS 1102 and nemorexant are dual antagonists that block both orexin receptors.

Items 26-27 of 27

  • Orexin B, human
    Cat. No.
    A62744

    Orexin B, human

    Synonyms: Human orexin B

    Orexin B (human) is an endogenous agonist that selectively targets the Orexin receptors, OX1 and OX2, with inhibition constants (Kis) of 420 nM and 36 nM, respectively. This compound plays a critical role in regulating arousal, appetite, and energy homeostasis. Orexin B is widely used in research applications focused on sleep disorders, metabolic syndromes, and neurodegenerative diseases, making it an essential tool for understanding Orexin signaling pathways.

    0.5 mg
    $1,145.00
    All 1 sizes
  • OX2R agonist 1
    Cat. No.
    A62749

    OX2R agonist 1

    OX2R Agonist 1 is a selective agonist of the orexin receptor 2 (OX2R), exhibiting an effective concentration (EC50) of less than 100 nM. This compound is instrumental in studying the neurobiology of sleep regulation and is particularly relevant for research focused on excessive daytime sleepiness and narcolepsy. Its potent biological activity positions it as a valuable tool in the exploration of treatments for sleep disorders.

    5 mg
    $350.00
    10 mg
    $650.00
    All 3 sizes

Items 26-27 of 27

Added to your cart

View Cart Checkout

    Loading...